Epidemiology, imaging, and treatment of giant cell arteritis

Joint Bone Spine

Volumn 75, Issue 3, 2008, Pages 267-272

  Devauchelle Pensec, Valérie ^a   Jousse, Sandrine ^a   Destombe, Claire ^a   Saraux, Alain ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Epidemiology; Giant cell arteritis; Imaging studies

Indexed keywords

ADALIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; HYDROCORTISONE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; RITUXIMAB;

AGRANULOCYTOSIS; CORTICOSTEROID THERAPY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FOLLOW UP; GIANT CELL ARTERITIS; HEMOLYSIS; HUMAN; METHEMOGLOBINEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SKIN TOXICITY; STROKE; TEMPORAL ARTERY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; FEMALE; GIANT CELL ARTERITIS; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 42749092917     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.09.008     Document Type: Short Survey

References (56)

1. Petursdottir V., Johansson H., Nordborg E., et al. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 38 (1999) 1208-1212
2. Salvarani C., Gabriel S.E., O'Fallon W.M., et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 123 (1995) 192-194
3. Haugeberg G., Paulsen P.Q., and Bie R.B. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 27 (2000) 2624-2627
4. Nordborg C., Johansson H., Petursdottir V., et al. The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. Rheumatology (Oxford) 42 (2003) 549-552
5. Kobayashi S., Yano T., Matsumoto Y., et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 49 (2003) 594-598
6. Salvarani C., Macchioni P., Zizzi F., et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 34 (1991) 351-356
7. Gonzalez-Gay M.A., Garcia-Porrua C., Rivas M.J., et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 60 (2001) 367-371
8. Sonnenblick M., Nesher G., Friedlander Y., et al. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br J Rheumatol 33 (1994) 938-941
9. Liu N.H., LaBree L.D., Feldon S.E., et al. The epidemiology of giant cell arteritis: a 12-year retrospective study. Ophthalmology 108 (2001) 1145-1149
10. Hachulla E., Boivin V., Pasturel-Michon U., et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 19 (2001) 171-176
11. Gonzalez-Gay M.A., Blanco R., Abraira V., et al. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 24 (1997) 2171-2176
12. Nordborg E., and Bengtsson B.A. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 299 (1989) 549-550
13. Uddhammar A., Eriksson A.L., Nystrom L., et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 29 (2002) 737-742
14. Gonzalez-Gay M.A., Rubiera G., Pineiro A., et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheumatol 32 (2005) 502-506
15. Pego-Reigosa R., Garcia-Porrua C., Pineiro A., et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol 6 Suppl 36 (2004) S13-S17
16. Liozon F., Vidal E., Gaches F., et al. Death in Horton disease. Prognostic factors. Rev Med Interne 13 (1992) 187-191
17. Schmidt W.A., Kraft H.E., Volker L., et al. Colour Doppler sonography to diagnose temporal arteritis. Lancet 345 (1995) 866
18. Schmidt W.A., Kraft H.E., Vorpahl K., et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 337 (1997) 1336-1342
19. Karassa F.B., Matsagas M.I., Schmidt W.A., et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 142 (2005) 359-369
20. Schmidt W.A., and Gromnica-Ihle E. What is the best approach to diagnosing large-vessel vasculitis?. Best Pract Res Clin Rheumatol 19 (2005) 223-242
21. Salvarani C., Silingardi M., Ghirarduzzi A., et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?. Ann Intern Med 137 (2002) 232-238
22. Reinhard M., Schmidt D., and Hetzel A. Color-coded sonography in suspected temporal arteritis-experiences after 83 cases. Rheumatol Int 24 (2004) 340-346
23. Hunder G.G., Bloch D.A., Michel B.A., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 (1990) 1122-1128
24. Bley T.A., Weiben O., Uhl M., et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 52 (2005) 2470-2477
25. Markl M., Uhl M., Wieben O., et al. High resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis. J Magn Reson Imaging 24 (2006) 423-427
26. Bley T.A., Ness T., Warnatz K., et al. Influence of corticosteroid treatment on MRI findings in giant cell arteritis. Clin Rheumatol 26 (2007) 1541-1543
27. Bley T.A., Uhl M., Venhoff N., et al. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol 26 (2007) 448-450
28. Turlakow A., Yeung H.W., Pui J., et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 161 (2001) 1003-1007
29. Blockmans D., de Ceuninck L., Vanderschueren S., et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 55 (2006) 131-137
30. Matteson E.L., Gold K.N., Bloch D.A., et al. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 100 (1996) 193-196
31. Gonzalez-Gay M.A., Blanco R., Garcia-Porrua C., et al. Long-term followup of patients receiving combined therapy with cyclosporine and methotrexate. Arthritis Rheum 41 (1998) 1703-1704
32. Chakravarty K., Elgabani S.H., Scott D.G., et al. A district audit on the management of polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 33 (1994) 152-156
33. Nuenninghoff D.M., and Matteson E.L. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 6 Suppl 32 (2003) S29-S34
34. Hayreh S.S., and Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110 (2003) 1204-1215
35. Salvarani C., Cantini F., Boiardi L., et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
36. Nordborg E., and Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol 16 (2004) 25-30
37. Myklebust G., and Gran J.T. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 30 (2001) 260-267
38. Gabriel S.E., Sunku J., Salvarani C., et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40 (1997) 1873-1878
39. Demaziere A. Dapsone in the long-term treatment of temporal arteritis. Am J Med 87 (1989) 3
40. Liozon F., Vidal E., Boutros-Toni F., et al. Clinical course of Horton disease. Apropos of 42 cured patients. Ann Med Interne (Paris) 145 (1994) 223-229
41. Roblot P. Immunosuppressive agents in Horton's disease. Which drug for which indication?. Ann Med Interne (Paris) 149 (1998) 441-447
42. de Vita S., Tavoni A., Jeracitano G., et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 232 (1992) 373-375
43. Le Guennec P., Dromer C., Sixou L., et al. Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients. Rhum Engl Ed 61 (1994) 485-490
44. Schaufelberger C., Mollby H., Uddhammar A., et al. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35 (2006) 327-329
45. Chevalet P., Barrier J.H., Pottier P., et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 27 (2000) 1484-1491
46. Mazlumzadeh M., Hunder G.G., Easley K.A., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54 (2006) 3310-3318
47. van der Veen M.J., Dinant H.J., van Booma-Frankfort C., et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?. Ann Rheum Dis 55 (1996) 218-223
48. Hoffman G.S., Cid M.C., Hellmann D.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
49. Jover J.A., Hernandez-Garcia C., Morado I.C., et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
50. Spiera R.F., Mitnick H.J., Kupersmith M., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001) 495-501
51. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
52. Ahmed M.M., Mubashir E., Hayat S., et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 26 (2007) 1353-1355
53. Leydet-Quilici H., Luc M., Armingeat T., et al. Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine 74 (2007) 303-304
54. Bhatia A., Ell P.J., and Edwards J.C. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64 (2005) 1099-1100
55. Nesher G., Berkun Y., Mates M., et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
56. Lee M.S., Smith S.D., Galor A., et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309